← Back to Episodes
PODCAST

Hot Flashes, Hard Feelings, and Red Angry Vulvas

October 6, 2026·9:40·Episode 139

Quick Summary

The American College of Physicians released a major new clinical guideline on medications for hot flashes and night sweats — and it has real implications for what treatment options your doctor will offer. This episode also covers the underreported connection between early menopause and anxiety and depression, and digs into vulvar skin changes: a common menopause symptom that rarely gets a proper exam.

Hot Flashes, Hard Feelings, and Red Angry Vulvas

0:000:00

Key Takeaways

  • ✦The ACP's new 2026 guideline recommends hormone therapy as a first-line treatment option for hot flashes and night sweats in women without contraindications — a meaningful signal for clinical practice.
  • ✦Non-hormonal options including fezolinetant (a newer prescription medication) are included in the guideline for women who can't or don't want to use hormones.
  • ✦Women who enter menopause early — before age 45 — report significantly higher rates of anxiety and depression, a mental health burden that is often not connected to menopause in clinical settings.
  • ✦Vulvar itching, burning, and irritation during and after menopause are real symptoms with identifiable causes — and "wait and see" is frequently the wrong advice.
  • ✦Many vulvar skin conditions are misdiagnosed or undertreated because clinicians skip the physical exam; a proper look changes the diagnosis in a meaningful number of cases.

Episode Script

Thanks Toni. We've got a genuinely good one today — let's get into it.

The American College of Physicians published a new clinical guideline this week on medications for hot flashes and night sweats. October 6th, 2026. Fresh off the press. The ACP, for anyone not familiar, is one of the largest physician groups in the United States — internists, primary care doctors, the people most likely to be the first one you talk to when you're struggling with symptoms. When they publish a guideline, it doesn't just sit in a journal. It shapes how doctors actually practice.

So what did they say?

Hormone therapy — estrogen, or estrogen plus progestogen for women with a uterus — comes out as a first-line option for treating hot flashes and night sweats in women without specific medical reasons to avoid it. That framing matters. For years, a lot of women heard "we can try hormones, but only as a last resort, and only for a short time." The evidence has been moving away from that for a while now, and this guideline formalizes the shift at a major institutional level. That's not nothing.

The guideline also covers non-hormonal options, which is where it gets interesting for women who can't use hormones — because of a history of certain cancers, blood clots, or other contraindications — or who just don't want to. Fezolinetant is in there. It's a prescription medication, relatively new, that works on a completely different pathway than hormones. It targets receptors in the brain that are involved in regulating body temperature, which is the actual mechanism behind hot flashes. It's not a supplement. It's not a wellness product. It's a drug with clinical trial data behind it, and the ACP is now recommending it as a legitimate option.

There are also older non-hormonal medications in the guideline — certain antidepressants used off-label, gabapentin. These have been around for a while, but they've often felt like the options nobody told you existed because they're not flashy and they're not marketed to you directly. Having them explicitly named in a major guideline should, in theory, make it easier for women to have that conversation with their doctor.

My honest read on this: the guideline is good. Not perfect. I'd want to see more data on long-term outcomes for fezolinetant specifically, and the evidence quality for some of the non-hormonal options is still moderate at best. But the direction is right. Hormone therapy is no longer being treated as the scary option of last resort, and non-hormonal choices are getting clearer clinical recognition. For women who've been told to just "manage it" or "wait it out," this is the kind of document you can actually bring to an appointment and say — these are the options, which one makes sense for me?

The part that deserves a little scrutiny: guidelines take time to trickle down. A primary care doctor who graduated ten years ago and gets maybe a few hours of continuing education on menopause per year isn't going to transform their practice overnight because of one document. The gap between what the guidelines say and what happens in a five-minute appointment is real, and it's frustrating. But having the guideline is step one.


The second thing I want to get into today is a pattern in the research that I think is significantly underappreciated: the connection between early menopause and mental health.

A study covered this week by News-Medical found that women who enter menopause early — roughly defined as before age 45, and sometimes called premature menopause if it's before 40 — report significantly higher rates of anxiety and depression compared to women who go through menopause at a more typical age.

This might sound obvious once you say it out loud, but it's actually being missed in clinical practice constantly. A woman in her late thirties or early forties who is anxious and depressed is very often being treated for anxiety and depression — full stop. The hormone piece, the early menopause piece, the context that might be driving or worsening her mental health — it doesn't always make it into the conversation.

Part of why this matters: the treatments can overlap, but they're not identical. Someone whose depression is connected to the hormonal upheaval of early menopause might respond differently to treatment than someone whose depression has a different origin. That doesn't mean hormones are a cure for depression — they're not, and I want to be clear about that. But the context changes the clinical picture, and right now a lot of women are losing that context because nobody connects the dots for them.

Early menopause also carries its own set of longer-term health implications — bone density loss starting earlier, cardiovascular changes, the mental health burden documented here — and the women experiencing it are often the least prepared for it. Menopause is something we culturally expect to happen to women in their early fifties. When it happens a decade earlier, women frequently describe feeling invisible in conversations about it, because the resources, the communities, the clinical attention — most of it is aimed at a different age group.

If you're in your late thirties or early forties and you're dealing with anxiety or depression and nobody has asked about your menstrual cycle changes or hormone levels, that's a conversation worth pushing for.


The third thing today comes from Dr. Kelly Casperson's podcast, You Are Not Broken, where she sat down with Dr. Melissa Mauskar, a vulvar dermatologist at UT Southwestern. The episode title is "Red Angry Vulvas, and Why Exams Matter," and I appreciate the directness.

Vulvar skin changes are a real and common part of the menopause picture. As estrogen drops, the tissue in the vulvar area — not just internally but the external skin — changes. It can become thinner, more sensitive, more prone to irritation. The medical umbrella for a lot of this is GSM — genitourinary syndrome of menopause — which covers dryness, discomfort, changes to the urinary tract, and changes to the vulvar tissue. It's not just a sex problem. It affects daily comfort, exercise, sitting down, wearing certain clothes.

What Dr. Mauskar makes clear in this conversation is that a huge number of women are walking around with vulvar itching, burning, or irritation that is being dismissed or mismanaged — and frequently it's being mismanaged because nobody did an actual exam.

She talks about how often women are told they have a yeast infection — sometimes repeatedly, over years — and treated with over-the-counter antifungal products that aren't doing anything because yeast isn't actually the problem. The problem might be a skin condition like lichen sclerosus, which is more common in menopausal and post-menopausal women and is often missed or delayed in diagnosis by years. It might be contact dermatitis from soaps, wipes, or other products. It might be something else entirely. But without looking — without an actual physical exam — the guess is often wrong.

The "wait and see" advice that a lot of women receive for these symptoms is particularly harmful when the issue is something like lichen sclerosus, because it's a progressive condition. It responds well to treatment, but untreated it can cause permanent changes to the tissue. Catching it early matters. Getting an exam matters.

Mauskar also talks about product use — soaps, douches, wipes, waxing — and the amount of unnecessary chemical irritation that a lot of women are unknowingly adding to already-sensitive tissue. Some of the products marketed specifically for "feminine hygiene" are, in her words, working against you. The vulva doesn't need to be cleaned with scented products. It needs to be left alone more than it's currently being left alone.

The throughline of this conversation is one I find genuinely useful: if you are experiencing itching, burning, or irritation in the vulvar area and you've been told it's normal or you should just moisturize or come back if it gets worse — you're allowed to push for an actual look. A clinical exam. Not a guess. That's not asking for too much. That's asking for the basic standard of care.

And if your current provider isn't comfortable with vulvar dermatology — that is a real specialty, it exists, and Dr. Mauskar's work is a good reminder that there are people who have made this their entire focus. You can ask for a referral.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.